<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072604</url>
  </required_header>
  <id_info>
    <org_study_id>14558</org_study_id>
    <nct_id>NCT01072604</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study Comparing Aspirin and Aspirin Granules</brief_title>
  <official_title>An Open Label Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Aspirin Tablets and Aspirin Dry Granules in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the bioequivalence of new formula of aspirin relative to the established
      commercial aspirin plain tablet and aspirin dry granules when taken orally by healthy adult
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence of new formula aspirin relative to the established commercial aspirin plain tablet and aspirin dry granules when taken orally by healthy adult subjects</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety and tolerability of the new aspirin formula</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess additional pharmacokinetic parameters</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid (Aspirin, BAY1019036)</intervention_name>
    <description>One oral dose of new formula Aspirin Prototype 1 under fasting conditions</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid (Aspirin, BAY1019036)</intervention_name>
    <description>One oral dose of new formula Aspirin Prototype 2 under fasting conditions</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid (Aspirin, BAYE4465)</intervention_name>
    <description>One oral dose of Aspirin Plain Tablet under fasting conditions</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid (Aspirin, BAYE4465)</intervention_name>
    <description>One oral dose of Aspirin Dry Granules under fasting conditions</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects between 18 to 55 years of age inclusive with a Body
             Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight &gt;50 kg (110
             lbs)

          -  Results of screening and clinical laboratory tests are within normal range or
             considered not clinically significant by the Principal Investigator or Sponsor

          -  Female subjects of childbearing potential must be using a medically acceptable form of
             birth control for at least 1 month prior to screening (3 months on oral
             contraceptives), e.g., oral or patch contraceptives, intrauterine device,
             Depo-Provera, or a double barrier and have a negative pregnancy test at Screening and
             Day 0 for each Dosing Period. Female subjects of non-childbearing potential must be
             amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy

          -  Be willing to participate in all scheduled visits, treatment plan, laboratory tests
             and other trial procedures according to the clinical protocol

        Exclusion Criteria:

          -  History of hypersensitivity to aspirin (ASA), NSAIDs, acetaminophen and similar
             pharmacological agents or components of the products

          -  Eighteen to twenty year olds with a viral infection, with or without fever, at the
             time of dosing

          -  Syndromes of asthma, rhinitis or nasal polyps

          -  Females who are pregnant or lactating

          -  Have taken ASA, ASA-containing products, acetaminophen or any other NSAID (OTC or
             prescription) 7 days prior to dosing or during the treatment period, other than trial
             treatment

          -  Smokers or currently consuming any type of tobacco product(s) including any smoking
             cessation nicotine-containing product (e.g., nicotine patch, nicotine gum)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <last_update_submitted>April 18, 2014</last_update_submitted>
  <last_update_submitted_qc>April 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>Acetylsalicylic Acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

